T-CELL LYMPHOMA MARKET ANALYSIS

T-cell Lymphoma Market, by Lymphoma Type (Peripheral T-cell Lymphoma (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)), and T-cell Lymphoblastic Lymphoma), by Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others (Antiviral Therapy, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Dec 2021
Code : CMI4799
Pages :168
Formats :
Excel and PDF
Industry : Biotechnology

Leading Companies

Key Players

Major players operating in the global T-cell lymphoma market include F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.